Lv2
118 积分 2024-01-22 加入
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
5天前
已完结
Efficacy of immunotherapy in RET fusion-positive NSCLC: A meta-analysis
25天前
已完结
Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer
1个月前
已完结
Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal
1个月前
已完结
More on Selpercatinib and Pseudo-Decreases in Kidney Function
4个月前
已完结
Safety evaluation of selective RET inhibitors in patients with lung cancer: a real-world pharmacovigilance study
4个月前
已完结
Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting
7个月前
已完结
Patient-Reported Outcomes of Postoperative NSCLC Patients with or without Staged Chinese Herb Medicine Therapy during Adjuvant Chemotherapy (NALLC 2): A Randomized, Double-Blind, Placebo-Controlled Trial
7个月前
已完结
Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer – Case Report
7个月前
已完结
Rearranged during transfection (RET) lung cancer – Update on targeted therapies
7个月前
已完结
皖公网安备34019202002308
